TABLE 2.
Summary of simulated ssAUC0–24 distributions for each study
| Author (yr) | % of subjects with ≥25% decrease in CLCR | 25th percentile ssAUC0–24 (mg · h/liter) | 50th percentile ssAUC0–24 (mg · h/liter) | 75th percentile ssAUC0–24 (mg · h/liter) |
|---|---|---|---|---|
| Ouderkirk et al. (2003) | NAa | 43.1 | 57.4 | 73.9 |
| Holloway et al. (2006) | 22.5 | 47.7 | 67.4 | 90.6 |
| Teng et al. (2007) | 19.0 | 28.5 | 42.4 | 58.9 |
| Pastewski et al. (2008) | 18.0 | 48.1 | 48.1 | 60.1 |
| Ramasubban et al. (2008) | 9.0 | 46.6 | 59.7 | 81.0 |
| Mendes et al. (2009) | 22.0 | 37.5 | 50.8 | 70.2 |
| Oliveira et al. (2009) | NA | 35.8 | 51.0 | 69.2 |
| Elias et al. (2010) | 50.6 | 49.4 | 77.1 | 117 |
| Kvitko et al. (2011) | 35.0 | 51.1 | 75.7 | 108 |
| Esaian et al. (2012) | 48.0 | 46.8 | 54.2 | 67.6 |
| Kubin et al. (2012) | 60.0 | 45.3 | 62.2 | 88.0 |
| Tuon et al. (2013) | 20.8 | 52.5 | 76.8 | 105 |
| Nandha et al. (2013) | 19.0 | 39.3 | 57.0 | 79.8 |
| Akajagbor et al. (2013) | 41.8 | 47.6 | 62.3 | 76.4 |
| Phe et al. (2014) | 23.1 | 39.2 | 52.8 | 69.8 |
| Rigatto et al. (2016) | 46.1 | 64.0 | 83.4 | 111 |
| Crass et al. (2017) | ||||
| Non-cystic fibrosis patients | 42.9 | 60.6 | 81.0 | 110 |
| Cystic fibrosis patients | 34.5 | 61.4 | 79.8 | 101 |
| Median (minimum–maximum) | 28.8 (9.0–60.0) | 47.2 (28.5–64.0) | 61.0 (42.4–83.4) | 80.4 (58.9–117) |
a
NA, not available.